Anu-Soma Healthcare: multi-dimensional, interactive digital technology patient treatments.
June 2024, hello and welcome. Anu-Soma Healthcare (USA) has originated three multi-dimensional prescription therapeutics to treat, improve and/or facilitate patient care. a.danu™ is an adjunct therapeutic that works synergistically with the primary treatment. unSpoken™ is a gynecologic first in class, stand alone primary treatment. WavePhysio™ is a stand alone treatment for an un-addressed, high disease burden condition. WavePhysio™ is also applicable as an interdisciplinary, post care rehabilitation therapeutic for select indications. Each innovative therapeutic applies personalized medical management for an International Classification of Disease prescribed indication.
Click on the logo image above for an overview of each product.
Anu-Soma’s participatory therapeutics are educative, introspective and actionable. Our Rx, patient centered medical treatments are coupled with digital technology, however these treatments are not telehealth, do not utilize a virtual counselor, and are not health coaching.
Anu-Soma’s FDA regulated, HIPPA compliant a.danu™ product is scheduled to enter the market during the fourth quarter of 2024. Our second medical product unSpoken™ is anticipated to enter the market during quarter two of the year 2025. Our third product WavePhysio™ is anticipated to enter the market during quarter four of the year 2025.
Each treatment has a tangible component that is integrated with interactive personalized digital technology. This patient centered dual functionality limits the human and economic burden that is often associated with these specific disease indications. Essentially, Anu-Soma has implemented a new therapeutic paradigm to improve the quality, the delivery and outcome of patient care.
Anu-Soma’s digital treatments are each regulated through the FDA – CDRH division via the 510(k) class II pathway. This digital component is termed software as a medical device. The software architecture is developed in the United States, under ISO 13485 standards.
The tangible components are manufactured in the United States in accordance with cGMP guidelines.
Each FDA regulated product is designed for at home patient use. These treatments uniquely expand management for early aging medicine – pre-habilitation, medical oncological care and gynecological care.
Click on the logo image below for an overview regarding the patient, the practitioner and the payor value of Anu-Soma’s multi-dimensional prescription treatments.
Note, this website provides a brief overview of Anu-Soma Healthcare LLC, more in-depth business to business dialogue is conducted via private communications.